For the first time, scientists have mapped the molecular wiring of Alzheimer’s and related brain diseases at single cell detail. This work breaks old limits on how these conditions are diagnosed and treated. The NIH-backed PsychAD Consortium built a single cell atlas of the human dorsolateral prefrontal cortex. They analyzed more than 6.3 million nuclei from 1,494 donors. These included people with Alzheimer’s, Parkinson’s, Lewy body disease, vascular dementia, schizophrenia, bipolar disorder, and healthy controls. The Mount Sinai Newsroom reports that this dataset covers a wide range of neurodegenerative and neuropsychiatric diseases. It gives a population-scale look at the brain’s molecular structure, down to each cell type and state.
The PsychAD dataset includes detailed subgroup sizes: 500 Alzheimer’s patients, 112 with diffuse Lewy body disease, 85 with vascular dementia, 40 with Parkinson’s disease, 47 with tauopathy, 15 with frontotemporal dementia, 120 with schizophrenia, and 55 with bipolar disorder.
Alzheimer’s and related dementias bring neuropsychiatric symptoms like depression, agitation, aggression, psychosis, insomnia, and irritability. These symptoms hit patients and families hard. They speed up the disease and often don’t respond to standard treatments. The NIH’s PsychAD program set out to crack the molecular code behind these symptoms. It also aims to explain why some psychiatric conditions in early and midlife raise the risk of dementia later on. The consortium started in 2019, funded by the National Institute on Aging and led by Mount Sinai researchers. They used a coordinated, multi-paper approach to make the biggest impact.
The new atlas shows both shared and disease-specific molecular changes across brain cell types. It traces how these changes link to Alzheimer’s progression and neuropsychiatric symptoms. Scientists found cell state shifts and regulatory programs that separate normal aging from disease. They mapped genetic risk variants to certain cell types and pathways. The team built an AI framework to spot cell states tied to pathology, cognitive decline, resilience, and neuropsychiatric features. The Mount Sinai Newsroom says the PsychAD project is a major NIH/NIA-backed push to uncover the molecular roots of neuropsychiatric symptoms and the links between early psychiatric illness and later dementia risk.
A separate lifespan analysis by the PsychAD consortium covered 284 individuals aged 0 to 97 years and profiled over 1.3 million cells from the prefrontal cortex, providing new insights into brain maturation and aging.
Panos Roussos, M.D., Ph.D., senior author and professor at the Icahn School of Medicine at Mount Sinai, summed it up: “By mapping shared and distinct cellular programs across Alzheimer’s disease, related dementias, and psychiatric disorders, PsychAD creates a framework for moving beyond traditional diagnostic boundaries toward precision approaches for target discovery, biomarker development, and therapeutic prioritization.”
The PsychAD Consortium’s open science model breaks from siloed research. It echoes the teamwork seen when Australia’s first single cell cancer proteomics lab opened in Sydney, as reported earlier.
With nine papers published across Nature and its journals, this project is more than a technical feat. It marks a turning point. The field now has a reference map to decode the molecular roots of neurodegenerative and neuropsychiatric disease, and the tools to chase precision medicine at the level of single cell states. The message is clear: the molecular fog around Alzheimer’s and related diseases is starting to clear. The path to targeted, effective treatments is coming into view. The era of one-size-fits-all dementia research is over.
